No, Cosentyx Is Not a TNF Inhibitor
Cosentyx (secukinumab) targets interleukin-17A (IL-17A), a cytokine involved in inflammatory pathways for conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis. TNF inhibitors, by contrast, block tumor necrosis factor-alpha (TNF-α), another key inflammatory mediator.[1]
How Cosentyx Differs from TNF Blockers
TNF inhibitors like Humira (adalimumab), Enbrel (etanercept), and Remicade (infliximab) bind TNF-α directly, reducing inflammation in autoimmune diseases. Cosentyx, an IL-17 monoclonal antibody, addresses a downstream pathway, making it suitable when TNF blockers fail or cause side effects.[1][2]
When Doctors Choose Cosentyx Over TNF Inhibitors
Physicians prescribe Cosentyx for patients unresponsive to TNF therapy or with specific IL-17-driven diseases. Clinical trials showed it cleared skin in 80% of psoriasis patients versus 10% on placebo, outperforming some TNF options in head-to-head studies for certain cases.[2]
Common TNF Inhibitors and Their Makers
| Drug | Active Ingredient | Manufacturer |
|------|-------------------|--------------|
| Humira | Adalimumab | AbbVie |
| Enbrel | Etanercept | Amgen/Pfizer |
| Remicade | Infliximab | Janssen |
| Cimzia | Certolizumab pegol | UCB |
| Simponi | Golimumab | Janssen |
Cosentyx, from Novartis, fits biologic DMARDs but not this TNF group.[1]
Side Effects: Cosentyx vs. TNF Inhibitors
Both classes raise infection risk, but Cosentyx links more to candida infections and IBD flares, while TNF blockers heighten TB and lymphoma risks. Monitor for hypersensitivity with all.[2]
Patent Status for Cosentyx
Cosentyx's main composition patent (US 7,807,155) expires in 2028 in the US, with pediatric exclusivity to 2029. No active challenges listed currently.[3]
[1]: FDA Label for Cosentyx - https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125504s006lbl.pdf
[2]: Cosentyx Prescribing Information - https://www.cosentyx.com
[3]: DrugPatentWatch.com - https://www.drugpatentwatch.com/p/tradename/COSENTYX